Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H9N3O |
| Molecular Weight | 151.1659 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CN=CC=C1N
InChI
InChIKey=MKZXMKBJWHAKIX-UHFFFAOYSA-N
InChI=1S/C7H9N3O/c1-5(11)10-7-4-9-3-2-6(7)8/h2-4H,1H3,(H2,8,9)(H,10,11)
| Molecular Formula | C7H9N3O |
| Molecular Weight | 151.1659 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:18:28 GMT 2023
by
admin
on
Sat Dec 16 15:18:28 GMT 2023
|
| Record UNII |
21G4M49F34
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
750570-35-5
Created by
admin on Sat Dec 16 15:18:29 GMT 2023 , Edited by admin on Sat Dec 16 15:18:29 GMT 2023
|
PRIMARY | |||
|
11593462
Created by
admin on Sat Dec 16 15:18:29 GMT 2023 , Edited by admin on Sat Dec 16 15:18:29 GMT 2023
|
PRIMARY | |||
|
21G4M49F34
Created by
admin on Sat Dec 16 15:18:29 GMT 2023 , Edited by admin on Sat Dec 16 15:18:29 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
EXCRETED UNCHANGED |
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE INACTIVE |
Genetic variants in the N-acetyltransferase gene 2 (NAT2) affect the rate and extent of AMIFAMPRIDINE metabolism. Poor metabolizers, also referred to as “slow acetylators” (i.e., carriers of two reduced function alleles), have 3.5-to 4.5-fold higher Cmax, and 5.6-to 9fold higher AUC than normal metabolizers, also referred to as “fast/rapid acetylators” (i.e., carriers of two normal function alleles). In the general population, the NAT2 poor metabolizer phenotype prevalence is 40–60% in the White and African American populations, and in 10–30% in Asian ethnic populations (individuals of Japanese, Chinese, or Korean descent).
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
|
|||